Skip to main content

Table 1 Patient background, dialysis condition, serum chemistries, comorbidities, and prescription status

From: Prescription characteristics of phosphate binders in a high pill burden for hemodialysis patients

Patients

n

533

Gender (male)

n (%)

362 (67.9)

Age

years

71.3 (63.8-78.0)

Dialysis vintage

years

5.5 (2.1-10.8)

Age of starting dialysis

years

63.9 (52.8-73.1)

Dialysis Modality

 HD

n (%)

306 (57.4)

 On-line HDF

n (%)

227 (42.6)

Time

 < 4 hr

n (%)

74 (13.9)

 4 hr

n (%)

443 (83.1)

 4.5 hr ≤

n (%)

16 (3.0)

Blood flow

 < 200 mL/min

n (%)

105 (19.7)

 200 mL/min

n (%)

214 (40.2)

 210 mL/min ≤

n (%)

214 (40.2)

Dialysate Ca

 2.5 mEq/L

n (%)

365 (68.5)

 3.0 mEq/L

n (%)

168 (31.5)

Serum corrected Ca

mg/dL

8.70 ± 0.61

Serum P

mg/dL

5.37 ± 1.17

Serum i-PTH

pg/mL

182 (120-257)

Comorbidities

 Diabetes mellitus (DM)

n (%)

310 (58.2)

 Heart failure

n (%)

155 (29.1)

 Angina

n (%)

85 (15.9)

 Myocardial infarction

n (%)

26 (4.9)

 Arrhythmia / Extrasystes

n (%)

80 (15.0)

 Peripheral vascular disease

n (%)

88 (16.5)

 Cerebral / Brainstem infarction

n (%)

106 (19.9)

 Neurologic / Psychiatric disease

n (%)

78 (14.6)

 Insomnia

n (%)

92 (17.3)

 Gastointestinal disease

n (%)

332 (62.3)

 Constipation

n (%)

141 (26.5)

 Diarrhea

n (%)

24 (4.5)

 Respiratory disease

n (%)

92 (17.3)

 Hepatobiliary disease

n (%)

132 (24.8)

 Pancreatic disease

n (%)

27 (5.1)

 Thyroid disease

n (%)

52 (9.8)

 Ocular disease

n (%)

263 (49.3)

 Joint and bone disease

n (%)

221 (41.5)

 Previous fracture

n (%)

65 (12.2)

 Malignancy (including history)

n (%)

135 (25.3)

 Gangrene, Cellulitis, Decubitus, Skin ulcer

n (%)

31 (5.8)

 Previous parathyroidectomy (PTx)

n (%)

10 (1.9)

Prescription medical doctors

n

26

Different types of oral drugs

 mean±SD

types/month/patient

9.2 ± 3.2

 median (Q1-Q3)

types/month/patient

9 (7-11)

Total pill burden

 mean±SD

pills/day/patient

15.1 ± 7.6

 median (Q1-Q3)

pills/day/patient

14.1 (10.0-18.7)

  1. HD hemodialysis, HDF hemodialysis filtration, Q1 first quartile, Q3 third quartile